Business
Posting of Annual Report & Notice of AGM
Posting of Annual Report & Notice of AGM.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 3753Z ValiRx PLC 26 May 2016 \n\n \n \n \nValiRx Plc\n(\"ValiRx\" or the \"Company\")\n \nPosting of Annual Report and Accounts\n&\nNotice of Annual General Meeting\n \n \nLondon, UK, 26 May 2016: ValiRx Plc (AIM: VAL) is a life science company with a focus on cancer therapeutics and diagnostics for personalised medicine. \n \nThe Company announces that its Annual Report and Accounts for the year ended 31 December 2015 has been published, are available on the Company's website, www.valirx.com and will be posted to registered shareholders shortly.\n \nThe Company also advises that the Notice of its Annual General Meeting (\"AGM\"), its Chairman's Letter to Shareholders and the Form of Proxy for the AGM are now available on its website, www.valirx.com and these will also be posted to registered shareholders.\n \nThe Company's AGM will be held on 20 June 2016 at 10.00am at the offices of Nabarro LLP at 125 London Wall, London, EC2Y 5AL.\n \n*** ENDS ***\n \nFor more information, please contact:\n \n\n\n\n\nValiRx plc\n\n\nTel: +44 (0) 20 3008 4416\nwww.valirx.com\n\n\n\n\nDr Satu Vainikka, Chief Executive\n\n\nTel: +44 (0) 20 3008 4416\n\n\n\n\nTarquin Edwards, Head of Communications.\n\n\nTel: +44 (0) 7879 458 364\[email protected]\n\n\n\n\nMark Treharne, Corporate Development Manager\n\n\nTel: +44 (0) 7736 564 686\[email protected]\n\n\n\n\n\n\n\n\n\n\n\n\nCairn Financial Advisers LLP (Nominated Adviser)\n\n\nTel: +44 (0) 20 7148 7900\n\n\n\n\nLiam Murray / Avi Robinson\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNorthland Capital Partners Limited (Broker)\n\n\nTel: +44 (0) 203 861 6625\n\n\n\n\nPatrick Claridge / David Hignell (Corporate Finance)\nJohn Howes / Abigail Wayne (Broking)\n\n\n\n\n\n\n\n \nNotes for Editors \nValiRx Plc\nValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.\n \nThe Company has undertaken to develop a novel and groundbreaking class of therapeutics across a number of fields in oncology and has taken its lead compound, Val201, into Pha...